Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen-receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05909397
What this trial is testing

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 59
Not applicableStudy completedNCT03961880
What this trial is testing

Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients

Who this might be right for
Breast Cancer Female
University Hospital Tuebingen 270
Testing effectiveness (Phase 2)Study completedNCT00424203
What this trial is testing

Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Who this might be right for
Breast CancerCognitive/Functional EffectsDepression+2 more
UNICANCER 40
Testing effectiveness (Phase 2)Looking for participantsNCT06964906
What this trial is testing

Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer

Who this might be right for
ER+/HER2- Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 30
Not applicableActive Not RecruitingNCT01824836
What this trial is testing

Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Who this might be right for
Estrogen Receptor-positive Breast CancerMusculoskeletal ComplicationsProgesterone Receptor-positive Breast Cancer+7 more
ECOG-ACRIN Cancer Research Group 1,046
Early research (Phase 1)Study completedNCT02338349
What this trial is testing

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Who this might be right for
Advanced ER+, HER2-Negative Breast Cancer
Stemline Therapeutics, Inc. 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04895358
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 342
Testing effectiveness (Phase 2)Looking for participantsNCT07631052
What this trial is testing

Capecitabine in ER+/HER2-negative Breast Cancer

Who this might be right for
ER-positive, HER2-negative Breast CancerBreast Cancer Stage IBreast Cancer Stage II+1 more
University Health Network, Toronto 15
Testing effectiveness (Phase 2)Looking for participantsNCT05386108
What this trial is testing

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Who this might be right for
Breast NeoplasmsBrain NeoplasmsNeoplasms by Site+5 more
Stemline Therapeutics, Inc. 73
Testing effectiveness (Phase 2)Looking for participantsNCT05181033
What this trial is testing

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
National University Hospital, Singapore 120
Large-scale testing (Phase 3)Study completedNCT02297438
What this trial is testing

Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Who this might be right for
Breast Neoplasms
Pfizer 340
Early research (Phase 1)Ended earlyNCT02414776
What this trial is testing

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy

Who this might be right for
Estrogen Receptor Positive Breast Cancer
Western Regional Medical Center 3
Not applicableStudy completedNCT02347449
What this trial is testing

The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population

Who this might be right for
Hormone Receptor Positive Malignant Neoplasm of Breast
Sunnybrook Health Sciences Centre 100
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Testing effectiveness (Phase 2)Study completedNCT03106077
What this trial is testing

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+18 more
M.D. Anderson Cancer Center 96
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Testing effectiveness (Phase 2)UnknownNCT05076695
What this trial is testing

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-positive Breast Cancer
Fudan University 37
Testing effectiveness (Phase 2)Study completedNCT00676663
What this trial is testing

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-Positive Breast CancerBreast Cancer, Estrogen Receptor-Positive+1 more
Syndax Pharmaceuticals 130
Testing effectiveness (Phase 2)WithdrawnNCT06613516
What this trial is testing

Effect of Capivasertib on ctDNA in ER Positive Breast Cancer

Who this might be right for
Breast CancerOestrogen Receptor Positive Breast Cancer
Imperial College London
Testing effectiveness (Phase 2)Study completedNCT03312738
What this trial is testing

Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 159
Next Page